Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma

• Status: Unknown status
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether an increase in the dose of carboplatin in treatment of advanced intraocular (group C and D) retinoblastoma helps in avoiding radiotherapy and improves the rate of globe salvage.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: All India Institute of Medical Sciences, New Delhi
• Collaborator: Council of Scientific and Industrial Research, India
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• All new cases of retinoblastoma with group C or D tumor as per the ICRB (International classification of retinoblastoma, Table 2) that present at Rajendra Prasad Centre for Ophthalmic Sciences over first 2 years of the study period

Exclusion Criteria:

• Biomicroscopic evidence of iris neovascularization

• Neovascular glaucoma

• Tumor invasion into the anterior chamber, iris, optic nerve, choroid, or extraocular tissues as documented by clinical, ultrasonographic, and neuroimaging modalities.

• Systemic exclusion criteria include:

• evidence of systemic metastasis

• prior chemotherapy

• prior treatment for retinoblastoma, or

• inadequate renal or hepatic function